TWI337080B - Prebiotic compositions - Google Patents
Prebiotic compositions Download PDFInfo
- Publication number
- TWI337080B TWI337080B TW092134808A TW92134808A TWI337080B TW I337080 B TWI337080 B TW I337080B TW 092134808 A TW092134808 A TW 092134808A TW 92134808 A TW92134808 A TW 92134808A TW I337080 B TWI337080 B TW I337080B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- grams
- gos
- patent application
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 93
- 235000013406 prebiotics Nutrition 0.000 title description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 235000016709 nutrition Nutrition 0.000 claims description 15
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 14
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 241000186000 Bifidobacterium Species 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 241000193403 Clostridium Species 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 235000010755 mineral Nutrition 0.000 claims description 6
- 241000606125 Bacteroides Species 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 244000005709 gut microbiome Species 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 238000006116 polymerization reaction Methods 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 11
- 150000002482 oligosaccharides Chemical class 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 9
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- -1 gums Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 229920000084 Gum arabic Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 4
- 239000001904 Arabinogalactan Substances 0.000 description 4
- 229920000189 Arabinogalactan Polymers 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 235000019312 arabinogalactan Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N Xylose Natural products O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 235000013570 smoothie Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000757373 Vibrio variabilis Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940029830 benefiber Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229910000420 cerium oxide Inorganic materials 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000015142 cultured sour cream Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KPPLIMDJGPOMAL-UHFFFAOYSA-K dipotassium;sodium;phosphate Chemical compound [Na+].[K+].[K+].[O-]P([O-])([O-])=O KPPLIMDJGPOMAL-UHFFFAOYSA-K 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010050792 glutenin Proteins 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000157 polyfructose Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002876 tegaserod Drugs 0.000 description 1
- CPDDZSSEAVLMRY-FEQFWAPWSA-N tegaserod maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 CPDDZSSEAVLMRY-FEQFWAPWSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Description
1337080 玖、發明說明: 【發明所屬之技術領域】 ’ 本發明關於一種益菌益生源組成物,其包括可溶性纖 維,特別是果寡糖類(fructo-oligosaccharides,FOS)以及 半乳寡糖類(galacto-oligosaccharides,G0S),和它們使 用於治療或預防月腸道疾病,例如炎症性腸.病( inflammatory bowel disease, IBD)、腹瀉和便秘。 ' 【先前技術】 益菌益生源(prebiotics )是不易消化的食物成分,其 對於健康有有益的效果。被歸類為益菌益生源之食物成分 必須滿足下列標準:i )不會被水解也不會被上胃腸道吸收 ’ Η)選擇性地被一種或有限數目之與大腸共生的潛在有 益菌發酵,例如乳酸桿菌及雙歧桿菌,其被刺激而生長及/ 或成為具代謝活性的,iii )可以改變大腸的微生物群落而 達到一較有益於健康的組成,例如藉由增加解糖物種的數 目而減少腐敗微生物。雙歧桿菌是必要的厭氧菌,其將醣 類主要代謝成為醋酸和乳酸,其進一步被系統性代謝。它 們被認為在腸的平衡、腐敗和致病菌的抑制、一些維生素 的產生、腸功能的活化、幫助消化和吸收以及免疫反錢 、 刺激上扮演-重要角色。因為雙歧桿菌對氧和熱敏感,它 們在食物的應用上已受到限制。因此對於顯示有效Ή 。 正常食物處理過程和選擇性標乾固有有益菌之益菌益生源 已有增高的興趣。 -種益菌益生源令人滿意的貢獻是有能力存留於大腸‘ 6 1337080 5〇重里。/。的四酿類’較佳為約5至約45重量%的四醣類, 更佳為約10至約40重量%的四醣類,及甚至更佳為約18 重里/〇的四膽類。根據本發明,GOS可包含,以GOS的總 重里什’約〇至約3〇重量%的五醣類’較佳為約1至約 25重量%的五醣類,更佳為約2至約1〇重量%的五醣類, 及甚至更佳為約7重量%的五醣類。 本文中使用的名詞『GOS』包含上文中定義之GO S及 反式半乳寡醣類,也稱為tG〇s。 GOS疋市售可獲得的,例如來自B〇rcui〇 D〇mo Ingredients (荷蘭)之Elix〇r®,其含有約58重量%的半 乳寡醣類、23重量%的乳糖及丨9重量%的葡萄糖;例如來 自 B〇rcul〇 Domo Ingredients (荷蘭)之 Vivinal®G0S 10 (粉末)’其含有約28重量%的半乳寡醣類、46.5重量% 的單聰類和雙醣類、17 5重量%的蛋白質、3丨重量%的礦 物質、1重量%的脂肪及4重量%的水分,又其亦可以下列 形式獲得:與50%乳清蛋白濃縮物(WPC35)之共同·噴霧 乾燥混合物,或來自Borculo Domo Ingredients (荷蘭) 之Vivinal GOS (糖漿),其含有75重量%乾燥物質,而 其中41重量%為單醣類和雙醣類而59重量%為G〇Sd 本發明組成物所含有的FOS和GOS的量可根據各種 相關因素來決定,包括給予的目的’各個體之年齡、性別 和體重’本發明組成物之形式(例如粉末或即可消耗( ready-f0r-C0nsumptl0n )的組成物’如即可飲用的組成物 或即溶飲料)及症狀的嚴重性。 13 1337080 公斤體重’更佳為約0.05克至約〇.4克,公斤體 佳為約0 · 1 0克至約0 · 3克/公斤體重。 FOS和GOS混合物的適當劑量,例如每 成介於約1克和約2〇克’較佳為介於約!克和約二構 更佳為介於約2克和約1 〇克,你丨 兄 兄例如可為約20克,較 約15克,更佳為約10克’甚至更佳為約5克。 為 於-方面,本發明提供一種本發明之組成物, FOS/GOS重量比為約〇.〇1至約5〇,較佳為約。…中 ,較佳為約0.1至約10,更佳兔糾 史佳為約0.2至約5,甚至 為約0.3至約3,最佳為約〇.5至約2,甚至最 至約1.5。FOS/GOS的重量比可約為i。 , ·〇 當然,本發明組成物之活性成分的相對比例將根據有 關的組成物之特定種類而非常多揭 .,,^ Β ㊉夕樣化,例如它是否為液體 或固體形A ’或它是否以營養形式提供。因此描述於本文 中之所有的指示比例和相對重量範圍應被理解為只是作為 較佳或個別發明教示之表示,而不將本發明限於其最大的 方面。 根據本發明,本發明之組成物可進一步包括不溶性及/ 或可溶性纖維,例如非·㈣多酿類,例如纖維素 '半纖維 素、抗性殿粉、膠類、纟耳膠、水解瓜耳膠,例如部分水 解瓜耳谬’可購自於例如Benefibre@ (由Ν〇ν_營養股 份公司)、果膠、阿拉伯膠及其混合物。 本發明之組成物也可包括多不飽和脂肪酸,且特別是 正-多不飽和脂肪酸,例如n_3脂肪酸及/或n_6脂肪醆’例 16 1337080 如α-次亞麻油酸(1 8:3 ) 、stearidonic acid、二十碳五稀酸 (ΕΡΑ) (20·5)、二十二碳五稀酸(22:5)及二十二破六 烯酸(DHA) ( 22:6)、亞麻油酸(18:2) 、γ·次亞麻油酸 (18:3)、二十碳四烯酸(2〇:4),呈游離形式或呈油或 脂的形式,及其混合物。較佳可使用二十碳五烯酸和二十 -一 六稀酸之混合物。 本發明之組成物亦可包括氮的來源,例如蛋白質及/或 胺基酸,及/或脂肪的來源(例如脂質),及/或醣類的來 源。本發明之組成物亦可含有維生素及/或礦物質。 本發明之另一具體實例中’本發明之組成物亦可包括 另外的寡醣類,例如乳酮糖、木糖寡醣(xos )、大豆寡 醣(SOS )、異麥芽寡醣(IM〇 )、阿拉伯半乳聚糖( arabinogalactan,ABG)、龍膽寡醣、聚果糖、部分水解瓜 耳膠(PHGG )及其混合物’較佳為。 於本發明之又一具體實例中,本發明之組成物實質上 或專有地(exclusively)由本文中所描述之F〇s和G〇s所 組成。 於本發明之一具體實例中’提供一種營養或醫藥組成 物,其包括由前文中所描述之F〇s和G〇s所組成之募醣 扣合物,例如由包括2至7個單醣單元之F〇s和包括2至 7個單醣單元之G0S所組成之混合物。 根據本發明組成物之另外的成分可包括任何生物活性 的化合物或卒取物,已知其具有健康益處,特別是對於腸 胃道有有益影響的化合物,例如麩胺醯胺/麩胺酸鹽或其前 17 1337080 驅物。 本發明之組成物亦可包含一或多種添加物質,其抑制 細菌附著於腸胃道的表皮壁,包括甘露聚糖、半乳糖醛酸 寡聚體’較佳為天然來源。本發明的組成物可以與有效於 治療潰瘍性結腸炎的藥物組合,例如美沙拉嗪( mesalamine )、柳氮磺胺毗啶' 5_ASA藥劑 '皮質類固醇 ’例如腎上腺類固醇、潑尾松龍(prednis〇ne )、氫皮質 綱(hydr0cortisone)或可滅喘(budes〇nide);或與用於 對抗疼痛、腹瀉和感染或IBS的藥物組合,例如一種血清 素-4文體激動劑,例如zelnorm/Ze】macTM。例如,本發明 之組成物可以合併的醫藥配製品或以套組的形式提供,用 於與前文所描述之該等藥劑分開、連續或同時共同施用。 這些藥劑可以方便地與本發明組成物以標準的醫藥劑型一 起配製。 於本發明之一具體實例中,本發明之組成物不包括 Ericaceae科之植物物種、或由小麥葉子衍生的物質。 於本發明之另一具體實例中,本發明之組成物不包括 棉子糖。 於本發明之一方面,根據本發明之組成物能無困難地 併入醫藥或營養配製品中,典型地為營養食品、飲食補充 物、醫療或功能性食品及飲料產品。 於本發明之又一方面,本發明之組成物可以用作為藥 劑。因此,本發明之組成物可以醫藥的形式或作為飲食補 充物給予,較佳係與至少一種醫藥或營養上可接受的載劑 18 1337080 這些營養組成物可以是營 去 Λ 魯几全地’亦即可包令雒咮 ’、礦物質、微量元素以及氮、醣翱# 它們可以用“ 虱醣類和脂肪酸來源,所以 3了以用作為提供實質上所有 脂肪酸、蛋白質以及類似物… 礦物貝、餹類、 。因此,太發μ 、 所需量的唯-營養來源 ,例如—+ 呂養千衡組成物之形式提供 J士元全配方飲食或完全牌今 食。 。 例如適合口服或管灌飲 或者,本發明的組成物可以提供Μ膳食的—部分, ρ種營養或飲食補充物,例如以健康飲料的形式。 以低卡路里組成物的形式提供本發明組成物是可令人 滿意的,例如膳食替代品。在營養組成物(例如膜食替代 品)的例子中,較佳為低脂,即以組成物的總卡路里含量 計’少於約ίο en%’或實f上無脂,即由脂肪所提供者少 於約2_5 en% ’如約2 en%脂肪。適當地’單份的低卡路里 營養組成物,例如膳食替代品,將具有少於約l〇〇〇kca]的 卡路里值’且較佳為介於約2〇〇kca丨和約5〇〇kcal。 適當的低卡路里營養組成物可包含清涼飲料,例如果 汁、思慕昔(smoothie )或以大豆為基底的飲料,或散佈 於任何種類的食物中,例如乳品棒(dairy bar),湯,榖 類食品,例如早餐的榖類加工食品,碾碎的榖物、堅果、 乾果等混合而成的瑞士風味的早餐食品(mues]i ),糖果 ’ tabs ’餅乾,小麵包(biscuit ),例如米果(rice cracker ),及乳製品例如奶昔、酸酪乳飲料、酸酪乳及水 果飲料。 20 7080 或者,本發明的組成物可提供作為高卡路里组成物 例如高卡路里飲食補充物或勝食替代品,例如具有高^ 4〇〇kCal的卡路里值,較佳為高於約6〇〇kca丨 ^力 約800kcal。 文佐马尚於 —根據本發明,本發明的組成物例如高卡路里组成物可 富含蛋白質,例如可含有,以組成物之總卡路里含量呀 2高於。約1⑽蛋白質(即每職…克),較佳為高於約 a’。蛋白質’更佳為高於約4 en%蛋白質,例如可含有約 1 :n%至約15 en%蛋白質,較佳為約2蛋白質至約 η/〇蛋白貝,更佳為約3 en%至約5 en%蛋白質。 本發明的組成物,例如高卡路里組成物可含有脂肪, ’以組成物之總卡路里含量計’高於⑽,較佳 回於5 ’更佳為高於6 en%,甚至更佳為高於7 en% ’且最佳為高於8 en%。 於本毛明之一具體實例中,提供一種组成物包括,例 :母1〇0毫升,約1至約3克F0S ’約1至約3克GOS, ::至20克蛋白質,,勺i至約3〇克醣類,約〇 5至約μ 1肪以及礦物質和維生素,較佳為約1 ·25克f〇S,約 、克G〇S,約9克蛋白質,約22克醣類和約9克脂肪 礦物質和維生素。這類組成物可以為完全配方飲食 、類組成物例如完全配方飲食可以是即可消耗的組成物 〇 本發明的組成物視需要地包括習用的食品添加物,例 士任何礼化劑、安定劑、增甜劑、調味料、著色劑、防腐 21 37080 劑、螯合劑、滲透劑、緩衝劑或pH調整劑、酸化劑、增 稠劑、調質劑等等。 根據本發明之適當的產品形式包括溶液,即可消耗的 之組成物例如即可飲用之組成物,即溶飲料,液態食品例 如清涼飲料、果汁、運動飲料、乳類飲料、奶昔、酸酿乳 飲料或湯。於本發明之另一具體實例中,本發明的組成物 可以濃縮物、粉末、或顆粒例如冒泡顆粒的形式製備及販 售’其係用水或其他液體(例如牛奶或果汁)稀釋,以產 生即可消耗的組成物’例如即可飲用組成物或即溶飲料。 於本發明之又一方面,提供一種本發明之組成物作為 食品添加物之用途。 本發明之醫藥組成物例如臨床產物及營養組成物例如 飲食補充物可以呈方便的劑型,以軟性凝膠、小藥囊( sachets)、粉末、糖聚、液態懸浮液 '乳化液及溶液的形 式提供。在軟性膠囊中’活性成分較佳係溶解或懸浮於適 當的液體中,例如脂肪油、石蠟油或液態聚乙二醇類。可 視需要添加安定劑。 口服醫藥或飲食補充物形式可以醫藥技藝中已知之習 用合成步驟製[也就是,藉由—起混合活性物質盘可食 的醫藥上可接受的固體或液體載劑及/或賦形劑,例如填充 劑,如纖維素、乳糖、嚴糖、甘露醇、山梨醇、及填酸妈 ’以及黏結劑,如殿粉、明膠、黃著膠、甲基纖維素及/或 聚乙彿m酮(PVP) ^需要的添加物包括潤滑劑和 流動έ周節劑例如石夕酸、二氧化矽、晋 3石 '硬脂酸、硬脂酸 22 1337080 表1使用FISH鑑定腸道微生物群落所使用的寡核苷酸探針 探針___標的種類 溫度
Bac 303 5'-CCAATGTGGGGGACCTT-3' 類桿菌屬 45〇C
Bif 164 5,-CATCCGGCATTACCACCC-3, 雙歧桿菌屬 50〇C
Erec 482 Chis 150 Ec 1531 Lab 158 Srb 687 5,-CGGUACCUGACUAAGAAGC-3, 5'-AAAGGAAGAUUAAUACCGCAUA-3' S'-CACCGTAGTGCCTCGTCATCAO1 5'-GGTATTAGCA(T/C)CTGTTTCCA-3. 5,-TACGGATTTCACTCCT-3· 擬球梭狀芽孢桿菌- <5〇°r Rectale真桿菌族群 溶組織梭狀芽孢桿菌族群50。〇 大腸桿菌 37°C 乳酸桿菌/腸球菌屬 45°C 多流弧菌 48。匸 人類臨床試驗實施如下: 於潰瘍性結腸炎病人進行隨機雙盲試驗,比較本發明 組成物(例如使用FOS之劑量範圍在約〇.〇1至約丨克/公 斤體重/曰’較佳為約0.05至約0.5克/公斤體重/日,更佳 為約0.1或0.15至約0.2克/公斤體重及G〇S之劑量範圍 在0_01至約1克/公斤體重/曰,較佳為約〇 〇5至約〇.5克/ 公斤體重/曰,更佳為約〇·1或〇·15至約〇.2克/公斤體重/ 曰)與標準營養補充物,其目的在於評估於12個月的治 療期間對腸功能、排泄物的微生物群落或大腸益菌益生源 發酵的功效。可測試3 0個病人。於每週評估下列來數: 糞便頻率、糞便中血液呈現、過多的黏液產生、糞便堅硬 度、胃氣脹、腸胃氣脹及腹部疼痛。藉由FIS Η鑑定排泄 物的微生物群落’並將有益菌種(例如乳酸桿菌和雙歧桿 菌)的數目和與疾病狀態有關之菌屬(例如梭狀芽抱桿菌 、類桿菌屬和硫酸鹽還原菌)的數目比較。亦測量翼便樣 品中短鏈脂肪酸(例如乙酸、丙酸、丁酸、乳酸和戍酸) 的濃度。使用PCR和DGGE進行所有糞便DNA萃取物之 27 1337080 研究。 本發明現在將進一步經以下列實施例說明。 31^11_丄.數種券聽及其混合物之益菌益生源的潛力 的活體外研究 使用作為正向對照之果寡醣類(F〇s)為法國Beghin· Meiji工廠之Actihght 95 0P® (含有92%果寡醣類)。 半礼寡膽類(GOS )為荷蘭FCDF之Elixor® (含有 58%寡醣類、23%乳糖及19%葡萄糖)。 木糖寡酿類(XOS)為曰本Sunt〇ry Limited之Xyl0_ oligo 95® (含有91 %寡醣類)。 大旦寡畴類(SOS )為日本Soya 〇Hg〇 Japan Inc之大 豆券醣類糖漿(Soybean 01igosaccharides Syrup)(含有 2 3 %券酶、21 %嚴糖、3 1 %其他醋類)。 阿拉伯半乳聚糖(ABG)為美國Larex Inc.之clear 1^〇八0-99@(含有95%可溶性纖維)。 阿拉伯膠(acacia gum,AG )也稱為阿拉伯樹膠( gummi arabicum)為法國 Colloides Naturels international 之Fibregum® (含有85 %可溶性纖維)。 小麥胚牙(WG)為 士 Multiforsa 之 Biogerm PB1® (含有32 0/〇寡醣類、30 %蛋白質、12 %纖維、7 %脂肪) 〇 異麥芽寡_類(IMO )為曰本showa Sangyo Co.之 Isomalto 900® (含有 89 %寡醣類)。 1.方法 28 1337080 有的細菌:類桿菌屬(spp‘)、雙歧桿菌屬( 請spp.)、擬球梭狀芽孢桿菌(c/〇川w請 /溶組織梭狀芽孢桿菌(…化如化請)次族群 和乳後桿菌(LaciobacUli )。 2. 結果 這裡所描述及討論的結果係6次合併的結果。各次為 不同的潛在的益菌益生源。 在發酵10和24小時之後,FOS + GOS被雙歧桿菌選擇 性且尚度地發酵。在這兩個時間點的增加均高於F〇s或 GOS單獨發酵的期間。類桿菌數目稍微下降。該組合顯示 所有文測試物質之乳酸桿菌最大的增加之一在於第—個】〇 小時的發酵期間。該增加並未持續到24小時之後,但數 目保持高於初始程度^雖然梭狀芽孢桿菌於1〇小時顯示 =少量增加,但數目在24小時後降到低於初始程度。類 桿菌數目在24小時後觀察到非常小的減少。f〇s + g〇s被 雙歧桿菌和乳醆桿菌快速地利用,且增加的數目遠高於單 獨的FOS或Gos。乳酸桿以1〇】、時的發酵後之相對 士的增加是非常重要的’因為益菌益生源通常會被雙歧桿 囷發酵’ ^致小的(如果有的話)乳酸桿菌的變化。該組 合似乎協乘性地增加有益細菌的數目。 3. 討論 —結果清楚的顯示’相較於本試驗所測試的可溶性纖維 ’养醣類係被有益細菌(主要是雙歧桿菌和乳酸 高選擇性地發酵。 ;更 30 1337080 合併FOS和GOS係協乘性作 祜罝3® 作用,而相較於這些寡醣
被早獨測试時,合併F〇s矛口 G .. 十思枓地嶒加雙歧桿 困和孔酸桿菌至較高的數量。鱼 , x、77開測忒的兩種寡醣相較 較不有益的細菌看似並未受合併 是稍微增加。由於它們的選擇性增加生長=減 匕們疋特別好的盈菌益生源。在受測試的所有成分和組合 中’ F0S和G0S之組合在整個發酵期間清楚地顯示是最好 的益菌益生源。 :營養組成物:1 〇〇克 1克 1克 0.2克 1克 0.43 克 0.28 克
FOS
GOS 水解的瓜耳膠⑴ 麩胺醯胺 二十碳五烯酸(EPA) 二十二碳六烯酸(DHA) ⑴得自 Novartis Nutrition Corporation 之 Benefiber®。 :宽施例3 :每100克營養組成物: 組成物為粉末形式,每日劑量(42克)應在取食前溶 解於大約200毫升冷水。 42.38 克 12.62 克 21.49 克 9.52 克 6.55 克
Vivinal®GOS 10(2) Actilight 950P FOS(3) 脫脂奶粉 全脂奶粉 可可香氣 31 1337080 MCT油 1.07 克 巧克力調味料 0.71 克 焦糖調味料 0.19 克 甜糖精-Na 0.07 克 純的香草酿 0.03 克 (2)得自 Borculo Domo Ingredients (荷蘭 ),其包含約 28 重量%GOS。 (3)來自 Beghin-Meiui industries (法國) ,其包含約92 重 量%FOS。 實施例 4 :即可飲 用飲食補充物, 每 100毫的 ( 1OOkcal) fos(4) 1.25 克 GOS(5) 1.25 克 蛋白質 9克 醣類 21.4
蔗糖 乳糖 脂肪 飽和F A 單不飽和FA 多不飽和F A 維生素A 維生素D 維生素E 5克 0.7克 0.81 克 4.84 克 2.54 克 % 8.7克 80微克 1微克 1毫克 32 1337080 維生素c 維生素κ 維生素B1 維生素B2 維生素B6 維生素B12 生物素 葉酸 於驗酸 泛酸(panthotenicacid) 鈉 鉀 鈣 磷 氣 鐵 鋅 銅 鉬 猛 鉻 石西 氟化物 6毫克 7微克 0.14毫克 0.16毫克 0.2毫克 〇-14微克 7.5微克 20微克 1 -8毫克 〇-6毫克 60毫克 160毫克 190毫克 30毫克 90毫克 70毫克 1.5毫克 1-5毫克 200微克 8微克 0.3毫克 10微克 6微克 150微克 33 1337080 碘 15微克 (4) 由 Vivina] GOS 得自 Borculo Domo Ingredients (荷蘭) (5) 由 Raftilose P95 得自 Orafti (比利時)
34
Claims (1)
1337080拾、申請專利範圍: :”、|f ;丨 \
1 . 一種營養組成物,包括果寡醣(F0S)及半乳寡醣 (GOS),其中FOS含有大於〇且至高約95重量%之由具 有聚合度範圍在約2至約7的鏈構成的寡果糖,及G〇s含 有大於0且至高約95重量%之由具有聚合度範圍在約2至 約7的鏈構成的寡半乳糖。
2. —種醫藥組成物,包括果寡醣(F〇s)及半乳寡醣 (GOS) ’其中f〇S含有大於。且至高約%重量%之由 具有聚合度範圍在約2至約7的鍵構成的寡果糖,及⑽ 含有大於〇且至高約95重量%之由具有聚合度範圍在約2 至約7的鏈構成的寡半乳糖。 3 ·根據申請專利範圍第1或2項之組成物,其中 FOS : GOS的重量比為約〇 2至約$。 4 .根據申請專利範圍帛1或2項之組成物,其 F〇S: G〇S的重量比為約0.5至約2。
5 .根據申請專利範圍帛1或2項之組成物,其 FOS和GOS混合物的量係構成在約2 〇和約^重量或 、之門以組成物的總重量或總體積計。 6.根據申請專利範圍第i或2項之組成物,其為 卡路里組成物。 圍第1 紐成物 圍第1 7 ·根據申請專利範 高於約len。/。蛋白質,以 8 .根據申請專利範 全配方飲食。 或2項之組成物’其包括 的總卡路里含量計。 或2項之組成物’其為完 35 丄jj/υδυ 令9 ‘根據申請專利範圍第i或2項之組成物,其每100 。 括、”勺1至約3克FOS、約1至約3克GOS、約2 至約2〇克蛋白質、約1至約30克醣類、約〇·5至約20克 脂肪,以及礦物質和維生素。 10 ·根據申請專利範圍第9項之組成物,其每1〇〇毫 升匕括.約1 ·25克F〇S、約1.25克GOS、約9克蛋白質 、約22克醣類及約9克脂肪。 U根據申请專利範圍第1或2項之組成物,是即可 消耗的組成物。 根據申靖專利範圍第1或2項之組成物,係用作 藥劑。 13根據申请專利範圍第1或2項之組成物’其進一 步包括麩胺醯胺。 14 . 一種根據申請專利範圍第1至13項中任一項之 組成物的用途,係用於製造治療或預防胃腸道疾病之藥劑 〇 15 . —種根據申請專利範圍第1至13項中任一項之 組成物的用途,係用於製造治療或預防腹瀉和便秘之藥劑 〇 10 . 一種根據申請專利範圍第1至13項中任一項之 組成物的用途,係用於製造治療或預防胃腸道疾病之營養 組成物。 1 7 . —種根擄申請專利範圍第丨至丨3項中任一項之 組成物的用途,係用於製造治療或預防腹瀉和便秘之營養 36 組成物。 18. -種根據申請專利範圍帛i至第ΐ3項中任一項 、且成物之用途,係用於製造維持及/或回復腸道微生物群 落之藥劑。 19·-種根攄申請專利範圍帛1至第13 #中任一項 之、.且成物之用途,係用於製造維持及/或回復腸道微生物群 落之營養組成物。 20 一種根據申請專利範圍第1至第13項中任一項 之、·=成物的用⑨,係用於製造預防或治療炎症性腸病,特 別是潰瘍結腸炎、Crohn氏疾病 '及/或防止大腸癌之藥劑 21 .—種根據申請專利範圍第 1至第13項中任一項 之”且成物的用it ’係用於製造預防或治療炎症性腸病 別疋潰癌結腸炎、Crohn氏疾病、 及/或防止大腸癌之營養 組成物。 22 . —種根據申請專利範圍第 1至第13項中任一項 ’且、的用途,係用於製造刺激雙歧桿菌及/或乳酸桿菌 生長及/或抑制至少一種類桿菌$、梭狀芽孢桿菌、大腸 菌、硫酸鹽還原菌的生長的藥劑。 —種根據申請專利範圍第1至第13項中任一項 之’.且成物的帛* u於製造刺激雙歧桿帛及/或乳酸桿菌 士長’及/或抑制至少—種類桿g屬、梭狀芽孢桿菌、大腸 囷、硫酸鹽還原菌的生長的營養組成物。 24 —種根據申請專利範圍第1至第13項中任一項 37 1337080 之組成物的用途,係用於製造預防或治療受致病腸道細菌 之感染的藥劑。 25 . —種根據申請專利範圍第1至第13項中任一項 之組成物的用途,係用於製造預防或治療受致病腸道細菌 之感染的營養組成物。 拾壹、圖式: 無
38
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0229015.3A GB0229015D0 (en) | 2002-12-12 | 2002-12-12 | New Compound |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200505462A TW200505462A (en) | 2005-02-16 |
TWI337080B true TWI337080B (en) | 2011-02-11 |
Family
ID=9949583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092134808A TWI337080B (en) | 2002-12-12 | 2003-12-10 | Prebiotic compositions |
Country Status (19)
Country | Link |
---|---|
US (2) | US7794746B2 (zh) |
EP (1) | EP1571923B1 (zh) |
JP (1) | JP4491348B2 (zh) |
CN (1) | CN1731938B (zh) |
AU (1) | AU2003294835B2 (zh) |
BR (1) | BRPI0317272B1 (zh) |
CA (1) | CA2508693C (zh) |
DK (1) | DK1571923T3 (zh) |
ES (1) | ES2449016T3 (zh) |
GB (1) | GB0229015D0 (zh) |
HK (1) | HK1083054A1 (zh) |
MX (1) | MXPA05006266A (zh) |
NZ (1) | NZ540576A (zh) |
PL (1) | PL213665B1 (zh) |
PT (1) | PT1571923E (zh) |
RU (1) | RU2358474C2 (zh) |
TW (1) | TWI337080B (zh) |
WO (1) | WO2004052121A1 (zh) |
ZA (1) | ZA200504385B (zh) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
US7608291B2 (en) * | 2000-03-10 | 2009-10-27 | Mars, Inc. | Treatment of infection in animals |
GB0229015D0 (en) | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
DE10328180A1 (de) * | 2003-06-16 | 2005-01-13 | Südzucker AG Mannheim/Ochsenfurt | Verwendung von Isomalt als Präbiotikum |
ES2284028T5 (es) * | 2003-06-30 | 2014-12-04 | Clasado Inc. | Nueva composición de galactooligosacárido y la preparación de la misma |
EP1597978A1 (en) * | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
EP1629727A1 (en) * | 2004-08-24 | 2006-03-01 | N.V. Nutricia | Composition containing fermentable polysaccharides |
EP1629850B2 (en) * | 2004-08-24 | 2013-05-22 | N.V. Nutricia | Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides |
KR101233648B1 (ko) * | 2004-09-29 | 2013-02-15 | 시즈오카켄 | 유청 단백, 젖 유래의 항체 또는 항체를 포함하는 기능성조성물 또는 식품 |
CA2601917C (en) * | 2005-02-21 | 2013-12-10 | Nestec S.A. | Oligosaccharide mixture |
US7572474B2 (en) * | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
US8143235B2 (en) * | 2005-12-16 | 2012-03-27 | N.V. Nutricia | Use of dietary fibres against muscle wasting |
GB0525857D0 (en) * | 2005-12-20 | 2006-02-01 | Product and process | |
GB0601901D0 (en) * | 2006-01-31 | 2006-03-08 | Product and Process | |
GB0606112D0 (en) | 2006-03-28 | 2006-05-03 | Product and process | |
DK2037937T3 (en) | 2006-05-30 | 2015-07-20 | Nutrition Sciences N V S A | TRI AND TETRA-OLIGOSACCHARIDES TO USE AS AGGLUTINATION AGENTS FOR ENTERIC PATHOGENS |
EP2076271B1 (en) * | 2006-10-02 | 2011-09-14 | Friesland Brands B.V. | Inhibition of cholera toxins by galatooligosaccharides (gos) |
WO2008090831A1 (ja) * | 2007-01-26 | 2008-07-31 | Amano Enzyme Inc. | 酵素組成物及びその用途 |
IL181431A0 (en) * | 2007-02-19 | 2007-07-04 | Micha Shemer | Fruit juice and puree with a lowered amount of available sugars |
US8463447B2 (en) | 2007-09-06 | 2013-06-11 | The Coca-Cola Company | Systems and methods for monitoring and controlling the dispense of a plurality of product forming ingredients |
RU2496711C2 (ru) | 2007-09-06 | 2013-10-27 | Дзе Кока-Кола Компани | Система и способ программирования вариантов дозирования в разливочном устройстве для приготовления продуктов |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
PL2589302T3 (pl) * | 2007-12-21 | 2017-05-31 | N.V. Nutricia | Zastosowanie sfingomieliny i niestrawnych węglowodanów do poprawiania mikroflory jelitowej |
WO2009087987A1 (ja) * | 2008-01-10 | 2009-07-16 | Nutri Co., Ltd. | 高齢者の栄養状態の改善、発熱回数の低下及び/又は免疫能向上のための組成物 |
GB0809921D0 (en) * | 2008-05-30 | 2008-07-09 | Clasado Inc | Product and process therefor |
DK2285387T3 (en) * | 2008-06-13 | 2016-01-25 | Nutricia Nv | Nutrition for preventing infections |
KR20110124780A (ko) * | 2009-02-24 | 2011-11-17 | 리터 파마슈티컬즈 인코오포레이티드 | 프리바이오틱 제제 및 사용 방법 |
CN101503720B (zh) * | 2009-02-24 | 2011-08-24 | 中国海洋大学 | 一种具有益生元作用的微生物寡糖的制备方法 |
US8425930B2 (en) * | 2009-03-13 | 2013-04-23 | The Regents Of The University Of California | Prebiotic oligosaccharides |
WO2010106384A1 (fr) * | 2009-03-16 | 2010-09-23 | Societe La Biochimie Appliquee (Solabia) | Compositions nutraceutiques, pharmaceutiques ou alimentaires a base de gluco-oligosaccharides |
WO2010117274A1 (en) * | 2009-04-08 | 2010-10-14 | Stichting Top Institute Food And Nutrition | Carbohydrates enhancing the production of a c5 and/or a c6 scfa |
GB0906983D0 (en) * | 2009-04-23 | 2009-06-03 | Clasado Inc | Novel use |
AU2009347008B2 (en) * | 2009-05-27 | 2013-08-15 | Clasado Limited | Method of preventing diarrhoea |
WO2010143940A1 (en) * | 2009-06-12 | 2010-12-16 | N.V. Nutricia | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages |
ES2651067T3 (es) * | 2009-07-06 | 2018-01-24 | Children's Hospital Medical Center | Inhibición de la inflamación con oligosacáridos de la leche |
WO2011020853A1 (en) | 2009-08-18 | 2011-02-24 | Cosucra-Groupe Warcoing Sa | Compositions containing mixtures of fermentable fibers |
GB0915315D0 (en) | 2009-09-03 | 2009-10-07 | Univ Manchester | Use of non-digestible oligosaccharides |
WO2011093907A1 (en) * | 2010-02-01 | 2011-08-04 | Corn Products International, Inc. | High-purity galactooligosaccharides and uses thereof |
WO2011137249A1 (en) * | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
BR112013004194A2 (pt) | 2010-08-25 | 2016-05-10 | Tate & Lyle Ingredients | produto simbiótico |
SG191394A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
US9539269B2 (en) | 2010-12-31 | 2017-01-10 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
EP2478779A1 (en) | 2011-01-24 | 2012-07-25 | Biotechnobel | Composition for providing beneficial health effects |
CN102613294A (zh) * | 2011-01-31 | 2012-08-01 | 内蒙古蒙牛乳业(集团)股份有限公司 | 一种低聚糖牛乳 |
JP5837315B2 (ja) * | 2011-03-25 | 2015-12-24 | イーエヌ大塚製薬株式会社 | 炎症性疾患用栄養組成物 |
EP2517699A1 (en) | 2011-04-29 | 2012-10-31 | Biotechnobel SA | Composition for prevention and treatment of arthritis |
ES2657744T3 (es) | 2011-07-22 | 2018-03-06 | Abbott Laboratories | Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal |
US9997006B2 (en) | 2011-08-26 | 2018-06-12 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
US10192037B2 (en) | 2011-08-26 | 2019-01-29 | Elwah LLC | Reporting system and method for ingestible product preparation system and method |
US8892249B2 (en) | 2011-08-26 | 2014-11-18 | Elwha Llc | Substance control system and method for dispensing systems |
US9947167B2 (en) | 2011-08-26 | 2018-04-17 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
US20130054255A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Controlled substance authorization and method for ingestible product preparation system and method |
US9111256B2 (en) | 2011-08-26 | 2015-08-18 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
US9785985B2 (en) | 2011-08-26 | 2017-10-10 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
US9922576B2 (en) | 2011-08-26 | 2018-03-20 | Elwha Llc | Ingestion intelligence acquisition system and method for ingestible material preparation system and method |
US9240028B2 (en) | 2011-08-26 | 2016-01-19 | Elwha Llc | Reporting system and method for ingestible product preparation system and method |
US10121218B2 (en) | 2012-06-12 | 2018-11-06 | Elwha Llc | Substrate structure injection treatment system and method for ingestible product system and method |
US9619958B2 (en) | 2012-06-12 | 2017-04-11 | Elwha Llc | Substrate structure duct treatment system and method for ingestible product system and method |
US8989895B2 (en) | 2011-08-26 | 2015-03-24 | Elwha, Llc | Substance control system and method for dispensing systems |
US10026336B2 (en) | 2011-08-26 | 2018-07-17 | Elwha Llc | Refuse intelligence acquisition system and method for ingestible product preparation system and method |
US20130330447A1 (en) | 2012-06-12 | 2013-12-12 | Elwha LLC, a limited liability company of the State of Delaware | Substrate Structure Deposition Treatment System And Method For Ingestible Product System and Method |
US9037478B2 (en) | 2011-08-26 | 2015-05-19 | Elwha Llc | Substance allocation system and method for ingestible product preparation system and method |
EP2750523A1 (en) | 2011-08-29 | 2014-07-09 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
RU2473347C1 (ru) * | 2011-11-09 | 2013-01-27 | Сергей Константинович Панюшин | Композиция пребиотиков для нормализации микрофлоры организма |
RU2484828C1 (ru) * | 2012-04-11 | 2013-06-20 | Анна Викторовна Филимонова | Витаминно-минеральное средство: порошок для приготовления раствора для внутреннего применения |
WO2013172714A1 (en) * | 2012-05-18 | 2013-11-21 | N.V. Nutricia | Treatment of conditions associated with mycotoxin exposure |
WO2013187755A1 (en) | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
CN102861108B (zh) * | 2012-09-07 | 2013-12-25 | 李宁 | 一种用于治疗便秘的药物组合物及其应用 |
US20140122120A1 (en) * | 2012-10-30 | 2014-05-01 | Pacesetter, Inc. | Systems and methods for providing photo-based patient verification for use with implantable medical device programmers |
US10626460B2 (en) | 2013-02-21 | 2020-04-21 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
GB201312713D0 (en) | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
GB201305708D0 (en) * | 2013-03-28 | 2013-05-15 | Clasado Inc | Novel use |
CN107001528A (zh) | 2014-07-09 | 2017-08-01 | 米德瑞(美国)有限公司 | 低聚糖组合物及其制备方法 |
US11173170B2 (en) * | 2014-11-05 | 2021-11-16 | Optibiotix Limited | Prebiotic composition and its methods of production |
CA2975095A1 (en) | 2015-01-26 | 2016-08-04 | Cadena Bio, Inc. | Oligosaccharide compositions for use as animal feed and methods of producing thereof |
EP3354282B1 (en) * | 2015-01-26 | 2020-12-30 | Kaleido Biosciences, Inc. | Glycan therapeutics and related methods thereof |
CA2983016A1 (en) * | 2015-04-23 | 2016-10-27 | Kaleido Biosciences, Inc. | Microbiome regulators and related uses thereof |
CN116270718A (zh) | 2015-04-23 | 2023-06-23 | Dsm营养产品有限责任公司 | 聚糖治疗剂和治疗方法 |
EP3288389A4 (en) | 2015-04-28 | 2018-10-10 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
GB201509023D0 (en) * | 2015-05-27 | 2015-07-08 | Optibiotix Ltd | Compositions and methods of production thereof |
AU2016102452A4 (en) * | 2015-06-23 | 2020-12-24 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children |
CN111888369A (zh) * | 2015-08-25 | 2020-11-06 | 卡莱多生物科技有限公司 | 聚糖组合物及其用途 |
MX2018002533A (es) | 2015-09-29 | 2018-06-27 | Kimberly Clark Co | Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora. |
CN105287561A (zh) * | 2015-11-25 | 2016-02-03 | 上海交通大学医学院附属瑞金医院 | 一种治疗溃疡性结肠炎的药物组合物 |
WO2017212064A1 (en) * | 2016-06-10 | 2017-12-14 | N.V. Nutricia | Risk of allergy and nutrition to reduce that risk |
EP3484483B1 (en) * | 2016-07-13 | 2023-03-08 | Kaleido Biosciences, Inc. | Glycan compositions and methods of use |
CN107927775A (zh) * | 2017-10-31 | 2018-04-20 | 天津市益倍建生物技术有限公司 | 一种含白藜芦醇的治疗溃疡性结肠炎的组合物 |
CN107981359A (zh) * | 2017-12-12 | 2018-05-04 | 河北三元食品有限公司 | 益生元组合物及其应用 |
CN107912589A (zh) * | 2017-12-21 | 2018-04-17 | 广州莱可福生物科技有限公司 | 含益生菌且可改善肠道和免疫力的压片糖果及其制备方法 |
CN108338984A (zh) * | 2018-02-26 | 2018-07-31 | 量子高科(中国)生物股份有限公司 | 具有清肠作用的组合物及其制备方法和在碳水化合物组件特医配方食品中的应用 |
EP3542641B1 (de) | 2018-03-20 | 2023-07-12 | Universität Hohenheim | Lactulosehaltiges produkt sowie verfahren zur herstellung eines lactulosehaltigen produkts |
SG11202104207TA (en) | 2018-11-08 | 2021-05-28 | Kaleido Biosciences Inc | Oligosaccharide compositions and methods of use thereof |
WO2020130775A1 (es) * | 2018-12-18 | 2020-06-25 | Centro De Retina Médica Y Quirúrgica, S.C. | Formulación de suplemento simbiótico para mejorar la microbiota intestinal |
CN110237092A (zh) * | 2019-06-11 | 2019-09-17 | 厦门蓝特生物科技有限公司 | 一种治疗便秘的组合物 |
CN112806577B (zh) * | 2019-11-15 | 2021-11-26 | 内蒙古伊利实业集团股份有限公司 | 产丁酸的益生元益生菌增效组合 |
JP7010509B2 (ja) * | 2020-01-15 | 2022-01-26 | 一般社団法人 Unical | 新規配合スポーツ飲料およびその調製のための顆粒剤 |
CN112641098A (zh) * | 2020-12-15 | 2021-04-13 | 山东欣瑞文生物科技有限公司 | 一种具有调理肠胃腹泻功能的阿拉伯胶组合物 |
KR102453998B1 (ko) * | 2022-01-07 | 2022-10-14 | (주)네오크레마 | 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04311384A (ja) | 1991-04-11 | 1992-11-04 | Calpis Food Ind Co Ltd:The | 植物組織培養方法及び植物組織培養用生長促進剤 |
US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
US5952314A (en) * | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
US5444054A (en) * | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
US5531989A (en) * | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
US5972905A (en) | 1995-06-14 | 1999-10-26 | Institute Of Immunology Co., Ltd. | Use of oligosaccharides for the treatment of pruritus cutaneus associated with renal failure |
EP1254664A3 (en) | 1995-07-10 | 2004-01-02 | Abbott Laboratories | Enteral products containing indigestible oligosaccharides for treating and preventing otitis media in humans |
US5827526A (en) * | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
DE69506095T2 (de) | 1995-08-04 | 1999-06-24 | Nutricia Nv | Diätfasern enthaltende Nahrungszusammensetzung |
MY115050A (en) * | 1995-10-16 | 2003-03-31 | Mead Johnson Nutrition Co | Diabetic nutritional product having controlled absorption of carbohydrate |
WO1997029763A1 (en) | 1996-02-14 | 1997-08-21 | The Procter & Gamble Company | Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor |
JP4008974B2 (ja) * | 1996-12-12 | 2007-11-14 | 森永乳業株式会社 | ビフィズス菌増殖促進組成物及びその用途 |
AU718640B2 (en) | 1996-12-20 | 2000-04-20 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | use of oligosaccharides to increase the sweetening power and enhance the taste of an acesulfame-K/aspartame mixture |
CA2294165C (en) * | 1997-07-05 | 2007-11-27 | Societe Des Produits Nestle S.A. | Frozen dessert |
JPH11302182A (ja) | 1998-04-16 | 1999-11-02 | Otsuka Pharmaceut Co Ltd | 抗水虫組成物 |
DE19836339B4 (de) | 1998-08-11 | 2011-12-22 | N.V. Nutricia | Kohlenhydratmischung |
IT1304170B1 (it) | 1998-12-15 | 2001-03-08 | Novartis Nutrition Ag | Composti organici |
NL1014380C2 (nl) * | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
CA2400969C (en) | 2000-03-01 | 2011-04-19 | Societe Des Produits Nestle S.A. | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response to measles vaccine |
EP1175905A1 (en) | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
JP2002051731A (ja) | 2000-08-11 | 2002-02-19 | Toyo Shinyaku:Kk | 麦若葉由来の素材を含む便秘改善食品 |
GB0028238D0 (en) | 2000-11-20 | 2001-01-03 | Cerestar Holding Bv | Indigestible oligosaccharides and magnesium absorption in humans |
ES2283462T3 (es) | 2000-12-27 | 2007-11-01 | N.V. Nutricia | Composicion nutricional con accion fomentadora de la salud conteniendooligosacaridos. |
GB0229015D0 (en) | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
JP4311384B2 (ja) | 2005-08-09 | 2009-08-12 | 日産自動車株式会社 | ハイブリット車両の発電制御方法 |
-
2002
- 2002-12-12 GB GBGB0229015.3A patent/GB0229015D0/en not_active Ceased
-
2003
- 2003-11-25 US US10/721,652 patent/US7794746B2/en active Active
- 2003-12-10 TW TW092134808A patent/TWI337080B/zh not_active IP Right Cessation
- 2003-12-11 CN CN2003801055586A patent/CN1731938B/zh not_active Expired - Lifetime
- 2003-12-11 EP EP03785796.8A patent/EP1571923B1/en not_active Revoked
- 2003-12-11 CA CA2508693A patent/CA2508693C/en not_active Expired - Lifetime
- 2003-12-11 NZ NZ540576A patent/NZ540576A/en unknown
- 2003-12-11 BR BRPI0317272A patent/BRPI0317272B1/pt active IP Right Grant
- 2003-12-11 PT PT37857968T patent/PT1571923E/pt unknown
- 2003-12-11 MX MXPA05006266A patent/MXPA05006266A/es active IP Right Grant
- 2003-12-11 RU RU2005121665/13A patent/RU2358474C2/ru not_active IP Right Cessation
- 2003-12-11 JP JP2004558076A patent/JP4491348B2/ja not_active Expired - Lifetime
- 2003-12-11 DK DK03785796.8T patent/DK1571923T3/en active
- 2003-12-11 AU AU2003294835A patent/AU2003294835B2/en not_active Expired
- 2003-12-11 PL PL377411A patent/PL213665B1/pl unknown
- 2003-12-11 ES ES03785796.8T patent/ES2449016T3/es not_active Expired - Lifetime
- 2003-12-11 WO PCT/EP2003/014087 patent/WO2004052121A1/en active IP Right Grant
-
2005
- 2005-05-30 ZA ZA200504385A patent/ZA200504385B/en unknown
-
2006
- 2006-03-09 HK HK06103077.4A patent/HK1083054A1/xx not_active IP Right Cessation
-
2010
- 2010-07-19 US US12/838,741 patent/US8241658B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PL213665B1 (pl) | 2013-04-30 |
ZA200504385B (en) | 2006-07-26 |
EP1571923A1 (en) | 2005-09-14 |
EP1571923B1 (en) | 2014-01-22 |
JP4491348B2 (ja) | 2010-06-30 |
US8241658B2 (en) | 2012-08-14 |
PL377411A1 (pl) | 2006-02-06 |
CA2508693A1 (en) | 2004-06-24 |
RU2005121665A (ru) | 2006-04-27 |
AU2003294835A1 (en) | 2004-06-30 |
PT1571923E (pt) | 2014-03-28 |
JP2006509797A (ja) | 2006-03-23 |
CN1731938A (zh) | 2006-02-08 |
BR0317272A (pt) | 2005-11-08 |
NZ540576A (en) | 2007-03-30 |
US20040131659A1 (en) | 2004-07-08 |
AU2003294835B2 (en) | 2007-05-03 |
RU2358474C2 (ru) | 2009-06-20 |
ES2449016T3 (es) | 2014-03-17 |
GB0229015D0 (en) | 2003-01-15 |
TW200505462A (en) | 2005-02-16 |
US20110003768A1 (en) | 2011-01-06 |
DK1571923T3 (en) | 2014-02-17 |
MXPA05006266A (es) | 2005-08-19 |
HK1083054A1 (en) | 2006-06-23 |
US7794746B2 (en) | 2010-09-14 |
BRPI0317272B1 (pt) | 2016-03-22 |
CA2508693C (en) | 2013-08-13 |
WO2004052121A1 (en) | 2004-06-24 |
CN1731938B (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI337080B (en) | Prebiotic compositions | |
US11696921B2 (en) | Synthetic composition for microbiota modulation | |
ES2702631T3 (es) | Composición nutricional con prebióticos y probióticos | |
JP5473190B2 (ja) | 化学療法又は放射線療法の副作用に対する栄養組成物 | |
US20200323921A1 (en) | Human milk oligosaccharides and synthetic compositions thereof for microbiota modulation | |
TW201233334A (en) | Human milk oligosaccharides to promote growth of beneficial bacteria | |
WO2009102193A1 (en) | A composition comprising bifidobacterium infantis and fructo- and galacto-oligosaccharides for the prevention of intestinal discomfort in infants | |
NZ534246A (en) | Stimulation of the immune system with polydextrose | |
US11541067B2 (en) | HMO compositions and methods for reducing detrimental proteolytic metabolites | |
RU2695699C2 (ru) | Питательная композиция с низким содержанием среднецепочечных жирных кислот в определенных соотношениях и ее применение | |
WO2023176952A1 (ja) | 腸管内での細菌の増殖制御用組成物及びその利用 | |
WO2022223961A1 (en) | Nutritional supplement and uses | |
JP2023062564A (ja) | 組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |